These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 228513)

  • 21. Histamine-sensitising factor of Bordetella pertussis differentiated from immunogens by neutralisation and passive protection tests.
    Preston NW; Garrity P
    J Pathol Bacteriol; 1967 Apr; 93(2):483-92. PubMed ID: 4293307
    [No Abstract]   [Full Text] [Related]  

  • 22. Acellular pertussis vaccines: neutralization by immune sera of the lethality of pertussis toxin and viable Bordetella pertussis for chick embryos.
    Calver GA
    Biologicals; 1999 Jun; 27(2):143-7. PubMed ID: 10600203
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the protective effects of the pertussis acellular vaccine with the component vaccine, which have different amounts of fimbriae, against the experimental aerosol infection of mice with Bordetella pertussis.
    Morokuma K; Ginnaga A; Nishihara T; Tsunoda S; Furukawa M; Aihara K; Sakoh M
    Dev Biol Stand; 1991; 73():223-32. PubMed ID: 1685713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of acellular pertussis vaccines-induced immunity against infection due to Bordetella pertussis variant isolates in a mouse model.
    Denoël P; Godfroid F; Guiso N; Hallander H; Poolman J
    Vaccine; 2005 Nov; 23(46-47):5333-41. PubMed ID: 16054273
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protective antigens of Bordetella pertussis mouse-protection test against intracerebral and aerosol challenge of B. pertussis.
    Sato H; Sato Y
    Dev Biol Stand; 1985; 61():461-7. PubMed ID: 2872127
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Passive protection of mice with the 19 S and 7 S fractions of anti-pertussis sera in experiment.
    Stanislavskii ES; Beilina VB
    J Hyg Epidemiol Microbiol Immunol; 1977; 21(3):301-8. PubMed ID: 203627
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development and clinical use of an oral heat-inactivated whole cell pertussis vaccine.
    Baumann E; Binder BR; Falk W; Huber EG; Kurz R; Rosanelli K
    Dev Biol Stand; 1985; 61():511-6. PubMed ID: 2872129
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Whooping cough in Finland 1920-1978. Statistical and epidemiological studies.
    Huovila R
    Acta Paediatr Scand Suppl; 1982; 298():1-29. PubMed ID: 6305107
    [No Abstract]   [Full Text] [Related]  

  • 29. Protective immunogenicity of synthetic peptides selected from the amino acid sequence of Bordetella pertussis toxin subunit S1.
    Askelöf P; Rodmalm K; Wrangsell G; Larsson U; Svenson SB; Cowell JL; Undén A; Bartfai T
    Dev Biol Stand; 1991; 73():111-20. PubMed ID: 1778305
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A modified schedule for routine pertussis immunization.
    Swartz TA; Roumiantzeff M; Peyron L; Stopler T; Kanaaneh H; Leitner L; Goldblum N
    Dev Biol Stand; 1985; 61():289-96. PubMed ID: 2872116
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lung pathology and immediate hypersensitivity in a mouse model after vaccination with pertussis vaccines and challenge with Bordetella pertussis.
    Vandebriel RJ; Gremmer ER; Vermeulen JP; Hellwig SM; Dormans JA; Roholl PJ; Mooi FR
    Vaccine; 2007 Mar; 25(12):2346-60. PubMed ID: 17224216
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationship between structure and biological and protective activities of pertussis toxin.
    Sato H; Sato Y
    Dev Biol Stand; 1991; 73():121-32. PubMed ID: 1723387
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aerosol infection test for evaluation of pertussis vaccine.
    Syukuda Y; Watanabe H; Suehara A; Fujii S; Kuno-Sakai H; Kimura M
    Tokai J Exp Clin Med; 1988; 13 Suppl():71-7. PubMed ID: 2908529
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis.
    Taranger J; Trollfors B; Lagergård T; Sundh V; Bryla DA; Schneerson R; Robbins JB
    J Infect Dis; 2000 Mar; 181(3):1010-3. PubMed ID: 10720524
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Serotyping of recently isolated strains of Bordetella pertussis. II. Disparity of agglutination titers of patients' sera between antigens prepared from the Maeno and recently isolated strains (author's transl)].
    Sekiya K; Yamada M; Takamiya A; Nakase Y
    Nihon Saikingaku Zasshi; 1979 Nov; 34(6):827-35. PubMed ID: 231129
    [No Abstract]   [Full Text] [Related]  

  • 36. [Consensus on the immunological defence of pertussis].
    Diao LD; Xu AQ;
    Zhonghua Liu Xing Bing Xue Za Zhi; 2011 Jun; 32(6):550-3. PubMed ID: 21781469
    [No Abstract]   [Full Text] [Related]  

  • 37. [Protection against infection with Bordetella pertussis by an oligopeptide from Bordetella pertussis (author's transl)].
    Wilhelm G; Römer C
    Zentralbl Bakteriol Orig B; 1978 Mar; 166(2-3):264-71. PubMed ID: 77606
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Whoop! There it is: The surprising resurgence of pertussis.
    Fullen AR; Yount KS; Dubey P; Deora R
    PLoS Pathog; 2020 Jul; 16(7):e1008625. PubMed ID: 32702023
    [No Abstract]   [Full Text] [Related]  

  • 39. The antibody activities of 19S and 7S fractions from rabbit antisera to Bordetella pertussis.
    Dolby JM; Dolby DE
    Immunology; 1969 Jun; 16(6):737-47. PubMed ID: 4306784
    [No Abstract]   [Full Text] [Related]  

  • 40. Factors influencing the stability of acid-precipitated polyvalent Bordetella pertussis bulk suspensions.
    Csizér Z; Zsidai J; Joó I
    Acta Microbiol Acad Sci Hung; 1975; 22(2):83-93. PubMed ID: 164759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.